KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Outstanding (2016 - 2025)

Biomarin Pharmaceutical's Shares Outstanding history spans 17 years, with the latest figure at $192.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 0.81% year-over-year to $192.3 million, compared with a TTM value of $192.3 million through Dec 2025, up 0.81%, and an annual FY2025 reading of $192.3 million, up 0.81% over the prior year.
  • Shares Outstanding for Q4 2025 was $192.3 million at Biomarin Pharmaceutical, roughly flat from $192.1 million in the prior quarter.
  • The five-year high for Shares Outstanding was $192.3 million in Q4 2025, with the low at $182.7 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $187.9 million, with a median of $188.2 million recorded in 2023.
  • Year-over-year, Shares Outstanding rose 1.46% in 2023 and then increased 0.81% in 2025.
  • Tracing BMRN's Shares Outstanding over 5 years: stood at $183.9 million in 2021, then rose by 1.27% to $186.3 million in 2022, then grew by 1.26% to $188.6 million in 2023, then rose by 1.15% to $190.8 million in 2024, then rose by 0.81% to $192.3 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Shares Outstanding are $192.3 million (Q4 2025), $192.1 million (Q3 2025), and $192.0 million (Q2 2025).